Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ranolazine (Roche Bioscience).

R Jones1

  • 1Trinity Cottage, Killiney, Co, Dublin, Ireland. rjj101@excite.com

Idrugs : the Investigational Drugs Journal
|August 23, 2005
PubMed
Summary
This summary is machine-generated.

Ranolazine significantly improved exercise duration and reduced angina symptoms in patients with stable angina. This metabolic modulator offers a new therapeutic option for heart conditions by enhancing cardiac energy metabolism without affecting heart rate or blood pressure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrastructural analysis of contractile cell development in lung microvessels in hyperoxic pulmonary hypertension. Fibroblasts and intermediate cells selectively reorganize nonmuscular segments.

The American journal of pathology·1992
Same author

ACP Broadsheet No 134: December 1992. How to harvest bone marrow for transplantation.

Journal of clinical pathology·1992
Same author

Identification of an abundant monkey epididymal transcript encoding a homologue of human CAMPATH-1 antigen precursor.

Biochimica et biophysica acta·1992
Same author

Eating habits and eating disorders during pregnancy.

Psychosomatic medicine·1992
Same author

Effect of radiation dose on the development of mixed haemopoietic chimerism following T cell-depleted allogeneic bone marrow transplantation.

Bone marrow transplantation·1992
Same author

Reasons for consultation in irritable bowel syndrome: symptoms and patient characteristics.

The British journal of general practice : the journal of the Royal College of General Practitioners·1992
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Medicine

Background:

  • Ranolazine is a novel metabolic modulator developed for angina treatment.
  • Current angina therapies can have limitations, necessitating new treatment options.

Purpose of the Study:

  • To evaluate the efficacy and safety of ranolazine in patients with stable angina.
  • To assess ranolazine's impact on exercise capacity and angina symptoms.

Main Methods:

  • The MARISA trial was a randomized, double-blind, placebo-controlled study of sustained-release ranolazine in 175 patients.
  • Patients received ranolazine (500, 1000, or 1500 mg bid) or placebo, with exercise duration as the primary endpoint.
  • The CARISA trial, a Phase III study, is evaluating ranolazine in combination with other anti-anginal drugs.

Related Experiment Videos

Main Results:

  • Ranolazine significantly increased treadmill exercise duration at all tested doses compared to placebo.
  • Key secondary endpoints, including time to angina onset and ischemia, were also significantly improved.
  • Phase II studies indicated ranolazine may increase exercise time without altering heart rate or blood pressure.

Conclusions:

  • Ranolazine demonstrates significant efficacy in improving exercise tolerance and angina symptoms in stable angina patients.
  • Its unique mechanism of improving cardiac energy metabolism offers a promising therapeutic approach.
  • Ranolazine may be a valuable option for patients unresponsive to conventional therapies.